: iStockAnalyst.com Symbols Feed

Celgene: Buy On A Pullback

Wed, 04 Nov 2009 17:04:19 GMT

“So why do we like Celgene so much, and how come we have time? The main reason I like it is its huge blood cancer drug Revlimid. $1.3 billion sales in 2008. It’s approved by the FDA to treat multiple myeloma. That’s a cancer of the plasma cells and bone marrow. These cancers are horrible…[More...]

Celgene (CELG): Bet On biotech

Wed, 21 Oct 2009 17:42:27 GMT

"I am recommending Celgene (NASDAQ: CELG) as part of an 'offense-defense' thesis," says Ian Wyatt. In Top Stock Insights, he reivews the leading biotechnology company.[More...]

Celgene Corporation (NASDAQ:CELG): Third Quarter Earnings Preview 2009

Mon, 12 Oct 2009 14:25:00 GMT

Celgene Corporation is scheduled to report its third quarter financial results on Thursday, October 22.[More...]

Insider Buys And Sells: Weekly Wrap-up

Mon, 21 Sep 2009 13:38:00 GMT

For all the analysts and pundits in the financial media, there is still no better judge of a company's health and future prospects than the owners and executives of those companies themselves, along with major institutional shareholders.[More...]

Celgene (Nasdaq: CELG): Cancer Progress Boosts Biotech

Tue, 18 Aug 2009 17:19:00 GMT

"Some sectors tend to do better than others in tough times; biotechnology often surprises investors in good times and bad," suggests Brandon Clay. In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review. "This sometimes-perilous market niche can make or[More...]

Biotech Portfolio Updates – Incyte (NASDAQ: INCY)

Tue, 11 Aug 2009 13:53:37 GMT

A drug with an almost certain approval and immediate sales potential of hundreds of millions of dollars is an asset very few biotech companies possess. In that sense, Incyte (INCY), which is developing a breakthrough drug for blood[More...]

Celgene (NASDAQ:CELG): Actionable Short Call Alert - Cowen

Thu, 06 Aug 2009 13:37:31 GMT

My favorite call today comes from Cowen. They are downgrading Celgene (NASDAQ:CELG) to Underperform from Neutral based on based upon concerns over 1) valuation, 2) the company’s ability to meet consensus revenue and earnings expectations and, 3) the potential for patent challenges to create an overhang on the stock. They expect CELG to underperform the market by 20%+ over the next 12 month Can Revlimid Be A $5B+ Drug? Celgene’s small molecule franchises have finite patent lives and its pipeline appears immature. Cowen's NPV analysis of the company’s oncology franchises suggests CELG shares are worth $45 assuming Revlimid sales reach $5B+ and the drug’s 2026 U.S. polymorph patent holds up to scrutiny. Sensitivity analyses indicate[More...]

Is It The Right Time To Buy Biotechnology Investments?

Thu, 30 Jul 2009 19:39:43 GMT

Share prices in the biotech sector have seen strong gains in recent weeks and it is logical to ask if it is too late to get on the biotech bandwagon. The answer, generally speaking, is no as long as investors get a few things right.[More...]

Why One Biotech Is Turning Heads: CELG

Wed, 29 Jul 2009 21:40:16 GMT

Some sectors tend to do better than others in tough times. Healthcare is one such area. Moreover, the biotechnology sub-sector often surprises investors in good times and bad. This sometimes-perilous niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals. Biotech ...[More...]

Nasdaq Rally Lives On - Major Averages Up 2%

Thu, 23 Jul 2009 20:25:00 GMT

Amazon.com and American Express are among many companies on tap to report results tonight after the bell. Stocks close higher as positive company news and home sales data overshadowed an earlier report showing a gain in weekly jobless benefits claims.[More...]

Finding the Road to Riches

Mon, 19 Oct 2009 15:46:00 GMT

Have you run across statements like this?
Of course, X is always a large number like $500,000 or $1 million.
Back when he made that investment, he paid a very large commission, as brokers charged a lot at the time and they also charged more for trades involving fewer shares than a "round lot" of 100.

: iStockAnalyst.com Symbols Feed

Celgene: Buy On A Pullback

Celgene (CELG): Bet On biotech

Celgene Corporation (NASDAQ:CELG): Third Quarter Earnings Preview 2009

Insider Buys And Sells: Weekly Wrap-up

Celgene (Nasdaq: CELG): Cancer Progress Boosts Biotech

Biotech Portfolio Updates – Incyte (NASDAQ: INCY)

Celgene (NASDAQ:CELG): Actionable Short Call Alert - Cowen

Is It The Right Time To Buy Biotechnology Investments?

Why One Biotech Is Turning Heads: CELG

Nasdaq Rally Lives On - Major Averages Up 2%

Finding the Road to Riches

Lennar, Wal-Mart, Jack in the Box big movers

Celgene Q2 Net Income Rises

Stocks Finish Mixed

Stocks: Finding Long-Term Winners

Taking Stock: Nobody Wins for 2008

Investors Can Consider No-Risk, Low-Risk Options

Health Care Poised to Weather Recession

Health care, defense poised to weather recession

Movers: AIG, Wal-Mart, Boeing, Ciena, Hovnanian

MethylGene Reports Third Quarter 2009 Financial Results

Celgene Reports Record Third Quarter 2009 Operating and Financial Results

Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments

GPC Biotech Reports Financial Results for Second Quarter and First Six Months of 2009

Clinical Data Evaluating Amrubicin® as Potential Therapy for Patients with Small Cell Lung Cancer Presented at 13th World Conference on Lung Cancer

VIDAZA Upgraded to Category 1 Based on Unprecedented Survival and Selected Preferred Treatment for Intermediate-2 and High-Risk Myelodysplastic Syndromes by the National Comprehensive Cancer Network (NCCN) in Its Clinical Practice Guidelines

Celgene Corporation to Present at Two Upcoming Investor Conferences

MethylGene Reports Second Quarter 2009 Financial Results

Celgene Reports Record Second Quarter 2009 Operating and Financial Results

Celgene Corporation to Announce Second Quarter Results on July 23, 2009

Form 4 CELGENE CORP /DE/ For: Oct 27 Filed by: Burton Graham (10K)

Form 4 GRYSKA DAVID W For: Oct 13 (10K)

Form 4 Burton Graham For: Oct 13 (10K)

Form 4 BARER SOL J For: Oct 13 (10K)

Form 4 HUGIN ROBERT J For: Oct 13 (10K)

Form 4 Van Hoek Andre For: Oct 13 (10K)

Form 4 HUGIN ROBERT J For: Oct 05 (10K)

Form 4 Van Hoek Andre For: Oct 01 (10K)

Form 4 BARER SOL J For: Sep 14 (10K)

Form 4 CELGENE CORP /DE/ For: Sep 04 Filed by: KAPLAN GILLA (10K)